Here are the Form 4 insider transactions from BioNTech (BNTX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BNTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BNTX filings page.
BioNTech SE (BNTX) Chief Executive Officer Ugur Sahin reported direct sales of 36,209 ordinary shares at $95.3733 per share on October 9, 2026, and 27,000 ordinary shares at $92.3142 per share on October 8, 2026. Both sales were effected pursuant to a Rule 10b5-1 trading plan established by Sahin on June 3, 2026.
At BioNTech SE (BNTX), Chief Executive Officer Ugur Sahin sold 24,000 ordinary shares at $95.8597 per share on October 7, 2026, under a Rule 10b5-1 trading plan established by him on June 3, 2026. His direct holdings after the sale were 63,209 ordinary shares. Separately, 39,218,111 ordinary shares were held through Medine GmbH, of which Sahin is the sole shareholder and may be deemed to beneficially own the shares. Of those shares, 106,721 were held for an individual's benefit under a trust arrangement; Medine GmbH exercised voting power but not dispositive power over them while they were held in trust.
BioNTech SE (BNTX) Chief Executive Officer and ten percent owner Ugur Sahin reported direct sales of 72,000 ordinary shares on October 5, 2026, at $97.2312 per share and 21,000 ordinary shares on October 6, 2026, at $96.8093 per share. The sales were made pursuant to a Rule 10b5-1 trading plan established June 3, 2026.
BioNTech SE (BNTX) Chief Executive Officer Ugur Sahin reported direct sales of 17,000 ordinary shares on October 1, 2026, at $97.4556 per share, and 17,000 ordinary shares on October 2 at $96.7249 per share. Both sales were made under a Rule 10b5-1 trading plan established by Sahin on June 3, 2026.
A separate indirect holding entry dated October 1 lists 39,218,111 ordinary shares held by Medine GmbH, whose sole shareholder is Sahin. Of those shares, 106,721 were held for an individual under a trust arrangement.
BioNTech SE Chief Executive Officer and 10% owner Ugur Sahin reported direct sales of 34,000 ordinary shares at $98.2591 per share on September 29, 2026, and 32,000 shares at $98.1203 per share on September 30. The sales were effected pursuant to a Rule 10b5-1 trading plan established June 3, 2026. An indirect holding entry dated September 29, 2026 reports 39,218,111 ordinary shares held by Medine GmbH; Sahin may be deemed to beneficially own those shares.
BioNTech SE Chief Executive Officer Ugur Sahin reported direct sales of 27,000 ordinary shares on September 25, 2026, at $98.6882 per share, and 34,000 ordinary shares on September 28, 2026, at $98.4682 per share. Both sales were effected pursuant to a Rule 10b5-1 trading plan established June 3, 2026. As of September 25, 2026, 39,218,111 ordinary shares were held indirectly through Medine GmbH, including 106,721 held for an individual's benefit under a trust arrangement in which Medine GmbH has voting but not dispositive power.
BioNTech SE Chief Executive Officer Ugur Sahin reported direct sales of 30,000 ordinary shares on September 23, 2026, at $99.4027 per share, and 39,000 shares on September 24 at $98.9913 per share. The sales were made under a Rule 10b5-1 trading plan established June 3, 2026. Separately, 39,218,111 ordinary shares were held indirectly through Medine GmbH as of September 23, 2026; Sahin is its sole shareholder and may be deemed to beneficially own them.
BioNTech SE (BNTX) reports that Chief Executive Officer and ten percent owner Ugur Sahin sold a total of 79,000 Ordinary Shares in open-market or private transactions on September 21–22, 2026, under a Rule 10b5-1 trading plan established on June 3, 2026. A form-level holding entry shows 39,218,111 Ordinary Shares held indirectly through Medine GmbH, of which 106,721 shares are held in trust where Medine GmbH has voting but not dispositive power; Sahin may be deemed to beneficially own the shares held by Medine GmbH.
BioNTech SE (BNTX) reports that Chief Executive Officer and ten percent owner Ugur Sahin sold a total of 64,000 Ordinary Shares in open-market or private transactions on September 17–18, 2026, at weighted-average prices of $98.5983 and $96.2243 per share, respectively, under a Rule 10b5-1 trading plan established on June 3, 2026.
Following these transactions, an entity associated with Sahin, Medine GmbH, holds 39,218,111 Ordinary Shares indirectly attributed to him, including 106,721 Ordinary Shares held in trust where Medine GmbH exercises voting power but not dispositive power, and Sahin may be deemed to beneficially own these shares.
BioNTech SE (BNTX) Chief Executive Officer and ten percent owner Ugur Sahin reported open-market sales of BioNTech ordinary shares under a pre-arranged Rule 10b5-1 trading plan established on June 3, 2026. He sold 15,000 ordinary shares on September 16, 2026 at an average price of $96.0893 per share and 34,000 ordinary shares on September 15, 2026 at an average price of $96.4893 per share, for total reported sales of 49,000 shares.
Following these transactions, a reported 39,218,111 ordinary shares are held indirectly through Medine GmbH, of which Sahin is the sole shareholder. The filing notes that 106,721 of these shares are held in trust, where Medine GmbH has voting but not dispositive power, and that Sahin may be deemed to beneficially own the shares held by Medine GmbH.
BioNTech SE (BNTX) reported that Chief Executive Officer and major shareholder Ugur Sahin sold a total of 86,000 ordinary shares in mid-September 2026 under a pre-arranged trading plan. He sold 41,000 shares on September 14, 2026 at an average price of 99.4467 per share and 45,000 shares on September 11, 2026 at an average price of 96.9338 per share.
After these sales, an entity associated with him, Medine GmbH, held 39,218,111 ordinary shares indirectly, including 106,721 shares held in trust where Medine GmbH has voting power but not dispositive power. The sales were effected pursuant to a Rule 10b5-1 trading plan established on June 3, 2026.
BioNTech SE (BNTX) reports that Chief Executive Officer and ten percent owner Ugur Sahin sold 20,500 Ordinary Shares on September 10, 2026 in an open-market or private transaction at $96.31 per share, under a Rule 10b5-1 trading plan established on June 3, 2026. Following this sale, he holds 688,209 Ordinary Shares directly and 39,218,111 Ordinary Shares indirectly through Medine GmbH, including 106,721 shares held in trust where Medine GmbH has voting but not dispositive power and Sahin may be deemed to beneficially own those shares.
BioNTech SE (BNTX) reported that Chief Executive Officer and ten percent owner Ugur Sahin sold ordinary shares in two open-market or private transactions under a pre-arranged Rule 10b5-1 trading plan established on June 3, 2026. On September 8 and 9, 2026 he sold an aggregate of 73,000 ordinary shares. An indirectly held position of 39,218,111 ordinary shares, mainly through Medine GmbH, is reported after these transactions.
BioNTech SE (BNTX) reported that Chief Executive Officer Ugur Sahin sold a total of 76,500 Ordinary Shares in open-market transactions pursuant to a Rule 10b5-1 trading plan established on June 3, 2026. The sales occurred on September 3 and September 4, 2026 at prices just above $102 and $103 per share.
BioNTech SE Chief Financial Officer Ramon Zapata Gomez received new equity-based compensation. He was granted 15,103 Performance Share Units and 18,879 options, each tied to one ordinary share. The options carry an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash.
Both the PSUs and options vest annually in equal installments over four years starting on the first anniversary of the grant. They become exercisable four years after the grant date and are subject to performance and other conditions, including share-price targets relative to the Nasdaq Biotechnology Index.
BioNTech SE reported new equity awards to officer Ryan James Timothy Patrick. On May 12, 2026, he received 10,069 Performance Share Units and an option over 12,586 ordinary shares as compensation, both at a grant price of zero.
The option carries an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the PSUs and options vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions. PSU performance targets are based on BioNTech’s share price relative to the Nasdaq Biotechnology Index.
BioNTech SE Chief Operating Officer Sierk Poetting reported compensation-related equity grants. He received 10,069 Performance Share Units and 12,586 options, each linked to ordinary shares. These awards were granted at no cash cost to him and are classified as derivative securities.
The options carry an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the options and PSUs vest annually in equal installments over four years starting on the first anniversary of the grant date and become exercisable four years after the grant date, subject to specified performance and service conditions.
BioNTech SE reported that Chief People Officer Kylie Jimenez received new equity-based compensation. She was granted 8,391 performance share units, each economically equivalent to one ordinary share, and options over 10,488 ordinary shares.
The performance share units and options both vest annually in equal installments over four years starting on the first anniversary of the grant date and become exercisable four years after the grant date, subject to performance-based and other conditions. The option has an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, and/or cash at the supervisory board’s election.
BioNTech SE Chief Commercial Officer Annemarie Hanekamp received new equity-based compensation awards. She was granted 10,069 performance share units and options on 12,586 ordinary shares, both with no upfront purchase price. The options have an exercise price of EUR 89.38 and may be settled in shares, ADSs, or cash at the supervisory board’s election. Both the options and PSUs vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions.
BioNTech SE Chief Operating Officer Sierk Poetting reported an indirect open-market sale of 50,000 Ordinary Shares. The shares were sold at an average price of $110.5592 per share and are held through Tofino GmbH, a company of which Poetting is the sole shareholder.
After this transaction, indirect holdings reported for Poetting through Tofino GmbH total 399,387 Ordinary Shares. This filing reflects a net sale, with no option exercises or derivative transactions disclosed in this report.